CORE16 Best of Breed Premier Index ETF (BOBP)

The CORE16 Best of Breed Premier Index ETF offers a refined version of U.S. equity exposure. Rather than holding the entire S&P 500 in equal or market-cap weighting, BOBP filters the universe of large-cap companies through a series of fundamental screens meant to identify businesses with real economic moats and resilient balance sheets.

The index methodology is straightforward in concept: select large-cap U.S. stocks, then rank them on metrics that proxy for quality. Typically, these include return on equity (a measure of how efficiently a company deploys its capital), debt-to-equity ratios (lower is favored), earnings stability, and accruals ratios (companies that report more cash profit than accounting profit are preferred). The “best of breed” name reflects the screening approach: instead of averaging the entire market, the fund concentrates on the top quartile or quintile of companies by quality score. This is a value-tilt execution — a recognition that not all large-cap stocks are equally likely to deliver durable returns.

BOBP’s holdings will look familiar: major U.S. corporations across technology, healthcare, energy, financials, and consumer sectors, but with a subtle overweight to companies with cleaner balance sheets and higher profitability relative to peers. Unlike an equal-weight or traditional market-cap-weighted index, BOBP rebalances based on its quality criteria, which means it tends to underweight expensive growth stocks and overweight profitable, less-leveraged companies. That rebalancing creates active risk — the fund will not perfectly track the broad market — but also the potential for outperformance in periods when quality-factor preferences dominate.

The expense ratio is reasonable for a factor-screened fund (around 0.55% to 0.65%), higher than a passive index tracker but lower than most actively managed funds. Trading volume is moderate; spreads are reasonably tight for a niche factor fund, though not as tight as the largest, broadest ETFs.

The risks are factor-dependent. When the market rewards growth, unprofitable companies, and leverage (as it did in parts of 2023–2024), a quality-screened fund will lag. The quality factor itself is mean-reverting — periods of strong quality outperformance are often followed by years of underperformance, and vice versa. Concentration is another concern: if the index methodology overweights a few mega-cap quality stocks, you may end up with a more concentrated portfolio than you realize, despite holding 500+ names. And because the index is reconstituted periodically based on updated fundamental data, there is an element of look-ahead bias in any backtest — the historical performance you see may be slightly better than what a live investor would have achieved if forced to choose holdings before seeing the latest quarterly earnings.

The fund suits long-term investors seeking U.S. equity exposure with a philosophical belief that quality (strong management, durable profitability, clean balance sheets) matters over time. It is not a growth play and not a value trap hunter; it is a middle way. Before committing, research the actual composition of the index: which stocks are overweighted and which are underweighted versus the S&P 500? How has the quality factor performed relative to the market over multiple market cycles? And understand that a factor-tilted fund is neither market-neutral nor neutral — it is making a bet on the persistence of a particular fundamental quality, which may or may not pay off depending on the regime.